# Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)

> **NCT02655419** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 40 (actual)

## Conditions studied

- Complicated Intra-Abdominal Infections, cIAIs

## Interventions

- **DRUG:** ATM-AVI
- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT02655419
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-19
- **Primary completion:** 2017-10-26
- **Final completion:** 2017-10-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655419, "Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02655419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*